Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18026356 | 0.72 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL3289374 | 0.70 | FDPS (0.34) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL19805314 | 0.69 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL3287592 | 0.69 | FDPS (0.37) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL337595 | 0.69 | MMP1 (0.34) | MMP1MMP2MMP3MMP8DGAT1 | |
| SCHEMBL2236605 | 0.67 | DGAT1 (0.35) | MMP1MMP2MMP3MMP8DGAT1 | |
| SCHEMBL7048472 | 0.67 | MMP1 (0.33) | MMP1MMP2MMP3MMP8DGAT1 | |
| SCHEMBL6088197 | 0.66 | FDPS (0.34) | MMP1MMP2MMP3MMP8 | |
| SCHEMBL23628722 | 0.64 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL26998813 | 0.64 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906015-A4 | LIVER RETENTION CLEARING AGENTS | NEORX CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-0906015-A1 | LIVER RETENTION CLEARING AGENTS | NEORX CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997046099-A1 | LIVER RETENTION CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |